PALMIRE cohort: phenotyping inflammatory lung diseases to enable personalized care
A Cohort for Inflammatory Respiratory Diseases: From Phenotyping to Personalised Medicine
This project will collect clinical, imaging, and biological data from adults with asthma, COPD, bronchiectasis, cystic fibrosis, primary ciliary dyskinesia, or interstitial lung disease to try to identify disease subtypes and markers that could guide more personalized care.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 470 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | CHU de Reims Academic / other |
| Locations | 1 site (Reims) |
| Trial ID | NCT07274631 on ClinicalTrials.gov |
What this trial studies
This monocentric, prospective cohort at the University Hospital of Reims will enroll adults with various chronic inflammatory lung diseases and healthy controls, with planned inclusion from July 2025 to July 2030. About 470 participants across disease groups (plus controls) will have detailed baseline data recorded and patients will be followed as part of usual care for up to 10 years. Collected data include demographics, disease history, symptoms, lung function tests, CT imaging, microbiology, pathology from respiratory samples when available, and exposure information. No experimental treatments are given; the project aims to link clinical, biological, and morphological features to underlying mechanisms and phenotypes.
Who should consider this trial
Good fit: Adults (≥18) followed at the University Hospital of Reims with a confirmed diagnosis of asthma, COPD, bronchiectasis, cystic fibrosis, primary ciliary dyskinesia, or interstitial lung disease, as well as healthy volunteers for the control group.
Not a fit: People unable to give informed consent, those legally protected, or patients who cannot attend baseline or routine follow-up visits are unlikely to benefit from participation.
Why it matters
Potential benefit: If successful, this work could help clinicians match treatments to each patient's disease phenotype and highlight new targets for therapy.
How similar studies have performed: Other longitudinal cohorts in asthma and COPD have successfully defined clinical and molecular phenotypes, but combining multiple inflammatory lung diseases in a single cohort for cross-disease phenotyping is less common.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age ≥ 18 years * Follow-up for one of the following conditions: asthma, COPD, bronchiectasis (DDB), cystic fibrosis (CF), primary ciliary dyskinesia (PCD), or interstitial lung diseases (ILD) * Healthy volunteers (controls) Exclusion Criteria: * Subjects protected by law (e.g., legal incapacity) * Any condition preventing informed consent or participation
Where this trial is running
Reims
- Chu Reims — Reims, France (Recruiting)
Study contacts
- Study coordinator: Jeanne-Marie PEROTIN-COLLARD
- Email: jmperotin-collard@chu-reims.fr
- Phone: 03 10 73 67 63
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.